Strategic report Governance & remuneration Financial statements Investor information Notes to the financial statements continued 10 Major restructuring costs Major restructuring costs charged in arriving at operating profit include restructuring costs arising under the Major Change programme initiated in 2013, under the Pharmaceuticals Restructuring Programme announced in October 2014 and following the Novartis transaction, completed in 2015.
For 2015, GSK is reporting these programmes together as one combined programme and the total restructuring costs of 1.9 billion in 2015 were incurred in the following areas: Restructuring of the Pharmaceuticals business in North America, Emerging Markets and Europe leading to staff reductions in sales force and administration.
Restructuring of the R&D organisation, predominantly in the United Kingdom, North America and Japan.
Projects to simplify or eliminate processes leading to staff reductions in support functions.
Transformation of the Manufacturing and Vaccines businesses to deliver a step change in quality, cost and productivity.
The integration of the Novartis Consumer Healthcare business to the new Consumer Healthcare Joint Venture.
The analysis of the costs charged to operating profit under these programmes is as follows: 2015 2014 2013 m m m Increase in provision for major restructuring programmes see Note 29 718 267 179 Amount of provision reversed unused see Note 29 44 411 Impairment losses recognised 419 60 Other non-cash charges 51 15 5 Other cash costs 747 472 284 1,891 750 517 Asset impairments of 419 million 2014 nil: 2013 60 million and other non-cash charges totalling 51 million 2014 15 million: 2013 5 million are non-cash items, principally xed asset write downs in manufacturing and research facilities and accelerated depreciation where asset lives in R&D have been shortened as a result of the major restructuring programmes.
All other charges have been or will be settled in cash and include the termination of leases, site closure costs, consultancy and project management fees.
11 Finance income 2015 2014 2013 m m m Interest income arising from: cash and cash equivalents 71 56 55 available-for-sale investments 1 12 derivatives at fair value through profit or loss 24 loans and receivables 3 92 Fair value adjustments on derivatives at fair value through profit or loss 5 22 104 68 61 All derivatives at fair value through profit or loss other than designated and effective hedging instruments see Note 41, Financial instruments and related disclosures are classied as held-for-trading financial instruments under IAS 39.
